A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Trial Profile

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Pelvic cancer; Urethral cancer; Urogenital cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-052
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 26 Sep 2017 Results (data cut off Sept 1, 2016) published in the Lancet Oncology
    • 12 Sep 2017 Results assessing efficacy of pembrolizumab as first-line therapy in a subgroup of senior patients with cisplatin-ineligible advanced urothelial cancer, presented at the 42nd European Society for Medical Oncology Congress.
    • 05 Sep 2017 According to a Merck AG media release, based on the results of this trial, the European Commission has approved pembrolizumab (KEYTRUDA) for the treatment of patients with locally advanced or metastatic urothelial carcinoma who are ineligible for cisplatin-containing chemotherapy.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top